Compare BATL & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BATL | MRKR |
|---|---|---|
| Founded | 1987 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 22.5M |
| IPO Year | 2004 | 2010 |
| Metric | BATL | MRKR |
|---|---|---|
| Price | $1.57 | $1.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 12.4M | 65.1K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.56 | 33.61 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $166,043,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $936.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $0.81 |
| 52 Week High | $29.70 | $2.46 |
| Indicator | BATL | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 48.86 | 38.05 |
| Support Level | $1.06 | $1.17 |
| Resistance Level | $2.42 | $1.54 |
| Average True Range (ATR) | 0.25 | 0.08 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 28.99 | 2.27 |
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).